SD-169

SKU: orb1299616

Description

SD-169 is a potent, ATP-competitive small molecule inhibitor selectively targeting p38α and p38β MAP kinases. It is widely used in research to investigate inflammatory pathways and cellular stress responses, with applications in both in vitro biochemical assays and in vivo disease models.

Research Area

Signal Transduction

Key Properties

• CAS Number: 1670-87-7
• MW: 160.17
• Purity: 98.60% (May vary between batches)
• Formula: C₉H₈N₂O
• SMILES: NC(=O)c1ccc2[nH]ccc2c1
• Target: p38 MAPK
• Solubility: 10% DMSO+40% PEG300+5% Tween 80+45% Saline:1 mg/mL (6.24 mM);DMSO:10 mg/mL (62.43 mM)

Bioactivity

• Target IC50:
  p38α MAPK:3.2 nM (IC50)|p38β MAPK:122 nM (IC50)
• In Vivo:
  Animals were gavaged with Scios SD-169 (10 or 30 mg/kg) or excipient (PEG300) 1 day before and daily after crush injury to the sciatic nerve. SD-169 is a proprietary oral inhibitor of p38 MAPK activity. The rate of axonal regeneration was determined by the functional pinch test and was significantly increased in treated animals 8 days after crush injury (P < 0.05; 30 mg/kg dose). In SD-169-treated animals with nerve transection, nerve fibers regenerating through a silicone chamber were morphologically more mature than untreated nerves when observed 28 days after transection. TNF immunofluorescence of distal nerve segments after crush injury suggested that SD-169 reduced SC TNF protein.
  Read more...

Storage & Handling

• Storage: -20°C
• Expiration Date: 12 months from date of receipt.
• Disclaimer: For research use only

Alternative Names

diabete, inhibit, kinases, p38MAPK, p38α, p38 MAPK, p38, mitogen-activated, Inhibitor, heat, MAPK, HSPs, shock, protein, proteins, SD169, SD-169, SD 169

Compound Identifiers

PubChem CID

14973220